ABUS
Arbutus Biopharma Corporation Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Arbutus Biopharma (ABUS) Stock: Buy, Sell, or Hold?
$4.09
+0.06 (+1.49%)
▲
5d:
+11.9%
30d:
-4.66%
90d:
-13.16%
QUANTITATIVE VERDICT
BUY
MODERATE Confidence (87%)
Quality Score
59/100
Position
FAIR
30-Day Fair Range
$3.91 – $4.36
Position: FAIR
Forward P/E & Valuation
-36.9x
Next 12M consensus est.
Wall Street Target
$5.35
+30.9% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$3.59 / $4.29
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
💡 BUY OPPORTUNITY: ABUS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
Get Alerted When ABUS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: ABUS is currently trading at $4.09, which is considered fair relative to its 30-day fair value range of $3.91 to $4.36.
Technical Outlook: Technically, ABUS is in a downtrend. Immediate support is located at $3.59, while resistance sits at $4.29.
Market Sentiment: ABUS scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.35 (+30.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ABUS is in a downtrend. Immediate support is located at $3.59, while resistance sits at $4.29.
Market Sentiment: ABUS scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.35 (+30.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.91 -
$4.36
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.8%
Trading Range & Key Levels
30-Day Trading Range
$3.91 -
$4.36
Current vs Trading Range
FAIR
Support Level
$3.59
Resistance Level
$4.29
Current Trend
Downtrend
Technical data as of
Nov 13, 2026
Quantitative Signal Breakdown
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (66/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 30.9% below Wall St target ($5.35)
- BULLISH: Bottoming setup score 66/100 — corrected, stabilizing, and turning up
Fundamental Context
Forward P/E (Next Year Est.)
-36.85
Wall Street Target
$5.35
(+30.9%)
Revenue Growth (YoY)
-43.5%
Profit Margin
121.2%
Share ABUS Analysis
Share this live ABUS analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (ABUS)
Bullish
3 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
2 msgs
24h retail stream
Last Tracked
Nov 13, 2026
Daily AI digest
AI Retail Discussion Summary:
Arbutus Biopharma and Genevant expanded patent infringement lawsuits against Pfizer and BioNTech, focusing on lipid nanoparticle composition in commercial vaccine samples. This raises questions about potential licensing costs and legal liabilities for BioNTech's mRNA vaccine franchise.
Key Retail Themes:
Patent lawsuits targeting BioNTech's mRNA vaccine technology
Potential impact on vaccine economics and licensing costs
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 13, 2026 4:58 PM ET
Data refreshes hourly during market hours. Next update: 5:58 PM
Data refreshes hourly during market hours. Next update: 5:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABUS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$302 | 60 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$592 | 40 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$304 | 39 SELL |
|
PVLA
Palvella Therapeutics, I… |
STRONG BUY
16 analysts |
$233 | 48 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$75 | 58 HOLD |
Advanced ABUS Option Strategies
Professional options setups generated by AI based on today's ABUS price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive ABUS Research Pages
